• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

August 5, 2019
Company Drug/Device Medical Condition Status
Miracor Medical SA PiCSO therapy heart attack Phase 1 trial initiated enrolling 114 subjects with anterior STEMI, TIMI 0 & 1 Flow, at nine clinical sites in Western Europe
Reflow Medical, Inc. Temporary Spur Stent System peripheral artery disease (PAD), occlusive disease affecting below-the-knee (BTK) arteries Phase 1 trial initiated
I-Mab Biopharma Tracon Pharmaceuticals, Inc. TJD5 (TJ004309) advanced solid tumors Phase 1 trial initiated
AC Immune SA ACI-35.030 Alzheimer’s disease (AD) Phase 1b/2a trial initiated
Proteostasis Therapeutics, Inc. cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations doublet (PTI-808 and PTI-801) and triplet (PTI-808, PTI-801 and PTI-428) cystic fibrosis (CF) Phase 2 trial initiated enrolling 30 F508del homozygous and 30 F508del heterozygous subjects
Arena Pharmaceuticals olorinab gastrointestinal (GI) disorders Phase 2 trial initiated enrolling 240 subjects experiencing abdominal pain associated with IBS, including IBS with constipation (IBS-C) or IBS with diarrhea (IBS-D) in sites across the U.S.
Relmada Therapeutics, Inc. REL-1017 (dextromethadone) treatment-resistant depression Phase 2 trial initiated enrolling 62 subjects
BELLUS Health Inc. BLU-5937 chronic cough Phase 2 trial initiated enrolling 65 subjects with refractory chronic cough at 12 sites in the U.S. and U.K.
Auris Medical Holding Ltd. AM-125 acute vertigo Phase 2 trial initiated enrolling 138 subjects who suffer from acute vertigo following surgical removal of a vestibular schwannoma in six European countries and Canada
Resolve Therapeutics RSLV-132 Systemic Lupus Erythematosus Phase 2a trial initiated enrolling 64 subjects at 20 sites across the U.S.
Abivax ABX464-301 moderate to severe active rheumatoid arthritis (RA) Phase 2a trial initiated enrolling 60 subjects in France, Poland, Czech Republic and Hungary
Modra Pharmaceuticals B.V. ModraDoc006/r metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 2b trial initiated enrolling 100 subjects with mCRPC eligible for first line systemic chemotherapy at 40 sites in the U.S. and Europe
Biohaven Pharmaceutical Holding Company Ltd. verdiperstat Multiple System Atrophy (MSA) Phase 3 trial initiated enrolling 250 subjects at 50 sites in the U.S. and Europe
AZTherapies, Inc. ALZT-OP1 early Alzheimer’s disease Phase 3 trial initiated enrolling 620 subjects with early stage Alzheimer’s disease, ages 55-79
Nektar Therapeutics Bristol-Myers Squibb bempegaldesleukin (NKTR-214) in combination with Opdivo (nivolumab) subjects with previously untreated unresectable or metastatic melanoma Breakthrough Therapy designation granted by the FDA
Endotronix, Inc. Cordella Pulmonary Artery (PA) Pressure Sensor System chronic heart failure IDE approval granted by the FDA
Intersect ENT PROPEL mini steroid Straight Delivery System (SDS) frontal and ethmoid sinus surgery Approval granted by the FDA
Retrophin, Inc. THIOLA EC (tiopronin) 100 mg and 300 mg tablets cystinuria Approval granted by the FDA
Merck KEYTRUDA (pembrolizumab) subjects with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) with disease progression after one or more prior lines of systemic therapy Approval granted by the FDA
Bayer Nubeqa (darolutamide) non-metastatic castration-resistant prostate cancer (nmCRPC) Approval granted by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing